Ending the Diagnostic Odyssey Act of 2021

Support for the UW System's 2022 Federal Priorities including the reauthorization of the Higher Education Act, STEM education and funding, efforts to support undergraduate research, and efforts to encourage teacher training and support. Support for the UW System's best practices on research security across entities and the organization. Support for the CHIPS Act of 2022 (H.R. 4346) and regional innovation center funding via the Consolidated Appropriations Act of 2023 (H.R.2617). Support for efforts related to public charter schools and efforts to support freedom of expression and civil dialogue on college campuses. Support for efforts related to the Department of Education's Student Loan Debt Relief Program. Support for campus entrepreneurship, innovation plans, and inclusive campus environments.

Client expense: $72,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support for the UW System's 2022 Federal Priorities which look to foster talent and diversity including support for comprehensive immigration reform that includes support for students brought to the United States as young children and international students who wish to remain post-graduation; support of efforts to improve the efficacy of visa processing; support of efforts to expand the Pell Grant Program to include DACA students.

Client expense: $72,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; S.2022, Ending the Diagnostic Odyssey Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

viral and human genomic research, testing,funding and insurance coverage, COVID-19 testing and research, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office

Human and Viral Genomic research, testing,funding and insurance coverage, pandemic preparedness, viral surveillance, Lab Developed Tests H791 and S236 COVID-19 Variants Data Tracking (viral sequencing and analytic supports) H6584 Clinical Trial Diversity H 7667 Rx Drug and Device User Fee Programs (regulation of Lab Developed Tests) H 4128 VALID Act (regulation of Lab Developed Tests) H 2471 Omnibus (PREVENT Pandemics Act, funding for Advanced Molecular Detection, and VALID Act) S2022 Whole Genome Sequencing Clinic (Whole Exome sequencing)

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office

H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding

Client expense: $1,380,000 · Firm income: Not reported

Issues related to genomics, sequencing, and surveillance; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Chips and Science Act (PL 117-167); H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; S. 3799, PREVENT Pandemics Act; S. 3534, Tracking Pathogens Act; Issues related to reauthorization of FDA user fee bills H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including H.R. 4281/S. 2209, VALID Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Ongoing monitoring of CDC surveillance funding; Chips and Science Act (PL 117-167); H.R. 791/S. 236, Tracking COVID-19 Variants Act; H.R. 5376, Inflation Reduction Act of 2022; H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; Issues related to the FY 2023 President's Budget; S.3534/H.R.7152, Tracking Pathogens Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including H.R. 4281/S. 2209, VALID Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support for the inclusion of higher education priorities in the budget, budget reconciliation efforts (H.R.5376 - Inflation Reduction Act, and similar Senate efforts), and FY23 appropriations legislation including efforts to expand the Pell Grant and increase the federal award amount, support for additional funding for federal research and research infrastructure. Continued support for including additional higher education funding, student mental health and academic success priorities in the budget and appropriations legislation. Support for the UW System's 2022 Federal Priorities including increased funding for: the National Institutes of Health, the National Science Foundation, the National Oceanic and Atmospheric Administration's National Estuarine Research Reserve, the Great Lakes Restoration Initiative, the U.S. Department of Agriculture's Capacity Building Grants for Non-Land Grant Colleges of Agriculture, and the Pell Grant Program, including allowing "DREAMers" to have access to the Pell Grant. Support for federal financial aid programs including: the Supplemental Educational Opportunity Grant, TRIO, GEAR UP, and the Pell Grant Program. Support for water sciences research, the Freshwater Collaborative of Wisconsin, and additional cybersecurity research and development. Support for increased STEM and water research funding via the FY23 appropriations process. Support of the CHIPS Act of 2022 (H.R. 4346), including support for the Small Business Innovation Research Program Reauthorization via this or other legislation. Support for research funding in H.R.3684 - Infrastructure Investment and Jobs Act.

Client expense: $84,000 · Firm income: Not reported

Support for the UW System's 2022 Federal Priorities including the reauthorization of the Higher Education Act, STEM education and funding, efforts to support undergraduate research, and efforts to encourage teacher training and support. Expressed concerns with the funding structure in the Opportunities for Success Act (H.R. 8343) and the Responsible Education Assistance through Loan (REAL) Reforms Act (H.R. 8655). Support for the CHIPS Act of 2022 (H.R. 4346) - including UW System's best practices on research security - and regional innovation centers. Support for efforts related to public charter schools and efforts to support freedom of expression and civil dialogue on college campus. Support for efforts related to the Department of Education's Student Loan Debt Relief Program.

Client expense: $84,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Vice President of the U.S.

Support for the UW System's 2022 Federal Priorities which look to foster talent and diversity including support for comprehensive immigration reform that includes support for students brought to the United States as young children and international students who wish to remain post-graduation; support of efforts to improve the efficacy of visa processing; support of efforts to expand the Pell Grant Program to include DACA students.

Client expense: $84,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance. S. 4348 - Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.

Client expense: Not reported · Firm income: $60,000

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; S.2022, Ending the Diagnostic Odyssey Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions

Client expense: $1,690,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to genomics, sequencing, and surveillance; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Monitor Conference negotiations between H.R. 4521, America COMPETES Act of 2022 and S. 1260, United States Innovation and Competition Act of 2021 and their efforts to bolster US competitiveness against China in critical technology sectors; H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; S. 3799, PREVENT Pandemics Act; S. 3534, Tracking Pathogens Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Ongoing monitoring of CDC surveillance funding; Monitor Conference negotiations between H.R. 4521, America COMPETES Act of 2022 and S. 1260, United States Innovation and Competition Act of 2021 and their efforts to bolster US competitiveness against China in critical technology sectors; H.R.791/S.236, Tracking COVID-19 Variants Act; H.R. 5376, Build Back Better Act; H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; Issues related to the FY 2023 Presidents Budget S.3534/H.R.7152, Tracking Pathogens Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; S.2022, Ending the Diagnostic Odyssey Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support for the inclusion of higher education priorities in the budget, budget reconciliation efforts (H.R.5376 - Build Back Better Act, and similar Senate efforts), and FY23 appropriations legislation including efforts to expand the Pell Grant and increase the federal award amount, support for additional funding for federal research and research infrastructure. Continued support for including additional higher education funding, student mental health and academic success priorities in the budget and appropriations legislation. Support for the UW System's 2022 Federal Priorities including increased funding for: the National Institutes of Health, the National Science Foundation, the National Oceanic and Atmospheric Administration's National Estuarine Research Reserve, the Great Lakes Restoration Initiative, the U.S. Department of Agriculture's Capacity Building Grants for Non-Land Grant Colleges of Agriculture, and the Pell Grant Program, including allowing "DREAMers" to have access to the Pell Grant. Support for federal financial aid programs including: the Supplemental Educational Opportunity Grant, TRIO, GEAR UP, and the Pell Grant Program. Support for water sciences research, the Freshwater Collaborative of Wisconsin, and additional cybersecurity research and development. Support for the national phenology network, the future of Naval capabilities advanced technology, liquid immersed future electronic power systems, and the Menomonie Street Corridor via the FY23 appropriations process. Support of the US Innovation and Competition Act (S.1260)/COMPETES Act (H.R.4521), including support for the Small Business Innovation Research Program Reauthorization. Support for research funding in H.R.3684 - Infrastructure Investment and Jobs Act.

Client expense: $62,000 · Firm income: Not reported

Support for the UW System's 2022 Federal Priorities which look to foster talent and diversity including support for comprehensive immigration reform that includes support for students brought to the United States as young children and international students who wish to remain post-graduation; support of efforts to improve the efficacy of visa processing; support of efforts to expand the Pell Grant Program to include DACA students.

Client expense: $62,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support for the UW System's 2022 Federal Priorities including the reauthorization of the Higher Education Act, STEM education and funding, efforts to support undergraduate research, and efforts to encourage teacher training and support. Support for the COMPETES Act (H.R.4521) /United States Innovation and Competition Act of 2021(S.1260) - including UW System's best practices on research security - and regional innovation centers.

Client expense: $62,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance. S. 4348 - Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.

Client expense: Not reported · Firm income: $60,000

Issues related to genomics, sequencing, and surveillance; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Monitor S. 1260, United States Innovation and Competition Act of 2021 and efforts to bolster US competitiveness against China in critical technology sectors; Monitor H.R.2731, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors; Monitor H.R. 4521, America COMPETES Act of 2022 and efforts to bolster US competitiveness against China in critical technology sectors; H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; S. 3534, Tracking Pathogens Act

Client expense: Not reported · Firm income: $60,000

Government targets: SENATE

H.R. 6000: Cures 2.0 Act; all provisions S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions General discussions related to genomics, sequencing and applications for sequencing technologies

Client expense: $1,960,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Implementation of American Rescue Plan Act of 2021 (PL 117-2); Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260); Ongoing monitoring of CDC surveillance funding; Monitor S. 1260, United States Innovation and Competition Act of 2021 and efforts to bolster US competitiveness against China in critical technology sectors; Monitor H.R. 2731, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors; Monitor H.R. 4521, America COMPETES Act of 2022 and efforts to bolster US competitiveness against China in critical technology sectors; H.R.791/S.236, Tracking COVID-19 Variants Act; H.R. 5376, Build Back Better Act; H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; Issues related to the FY 2023 Presidents Budget S.3534/H.R.7152, Tracking Pathogens Act

Client expense: Not reported · Firm income: $60,000

Issues related to defense research; science and security, UARCS, and high-skilled immigration. H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 and FY's 2022 and 2023 Department of Defense Appropriations.

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues regarding FY's 2022 and 2023 Transportation Housing & Urban Development Appropriations as related to University transportation centers and transportation research.

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Congressional Personalized Medicine Caucus H.R. 5989 Precision Medicine Answers for Kids Today Act S. 2022 Ending the Diagnostic Odyssey Act H.R. 6000 Cures 2.0 H.R. 6875 Right Drug Dose Now Act H.R. 4128/S.2209 The VALID Act of 2021 H.R. 6202 the Telehealth Extension Act S. 3593 the Telehealth Extension and Evaluation Act Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community CMS Transitional Coverage of Emerging Technology (TCET) CMS Transmittal 10832 Removal of ICD-10 Not Otherwise Specified (NOS) Codes Under National Coverage Determination (NCD) 90.2 CMMI Oncology Care Model/Oncology Care First

Client expense: $42,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; S.2022, Ending the Diagnostic Odyssey Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support for the inclusion of higher education priorities in the budget, budget reconciliation efforts (H.R.5376 - Build Back Better Act, and similar Senate efforts), and omnibus appropriations bill (Consolidated Appropriations Act, 2022) including efforts to expand the Pell Grant and increase the federal award amount, support for additional funding for federal research and research infrastructure. Continued support for including additional higher education funding, student mental health and academic success priorities in the budget and appropriations legislation. Support for the UW System's 2022 Federal Priorities including increased funding for: the National Institutes of Health, the National Science Foundation and NSF's Flex Ride program, the National Oceanic and Atmospheric Administration's National Estuarine Research Reserve, the Great Lakes Restoration Initiative, the U.S. Department of Agriculture's Capacity Building Grants for Non-Land Grant Colleges of Agriculture, and the Pell Grant Program, including allowing "DREAMers" to have access to the Pell Grant. Support for federal financial aid programs including: the Supplemental Educational Opportunity Grant, TRIO, GEAR UP, and the Pell Grant Program. Support for efforts to fund broadband access and additional cybersecurity research and development. Support for water sciences research, the Freshwater Collaborative of Wisconsin, and the Connected Systems Institute. Support for a Great Lakes research vessel, Small Business Development Center, and the Center for Economic Development via the FY22 appropriations process. Support of the US Innovation and Competition Act (S.1260)/COMPETES Act (H.R.4521). Support for research funding in H.R.3684 - Infrastructure Investment and Jobs Act.

Client expense: $61,000 · Firm income: Not reported

Support for the UW System's 2022 Federal Priorities which look to foster talent and diversity including support for comprehensive immigration reform that includes support for students brought to the United States as young children and international students who wish to remain post-graduation; support of efforts to improve the efficacy of visa processing; support of efforts to expand the Pell Grant Program to include DACA students.

Client expense: $61,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance.

Client expense: Not reported · Firm income: $50,000

Healthcare issues related to clinical laboratories; H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; H.R. 6202, the Telehealth Extension Act, and S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests; S. 3534, the Tracking Pathogens Act, provisions relating to genomic sequencing of variants of the SARS-CoV-2 virus; S. 3799, the PREVENT Pandemics Act, and a draft of the Improving DATA in Public Health Act, provisions relating to demographic data reporting obligations for laboratories; Federal policy related to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; and H.R. 6875, the Right Drug Dose Now Act, provisions relating to use of pharmacogenetic information; H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research; and Federal policy relating to CDC funding for standardization of pediatric reference range intervals and laboratory result harmonization.

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; S.2022, Ending the Diagnostic Odyssey Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2022, The Diagnostic Odyssey Act and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance.

Client expense: Not reported · Firm income: $50,000

Issues related to genomics, sequencing, and surveillance; S. 2022, Ending the diagnostic Odyssey Act; CURES 2.0 Discussion Draft; Monitor S. 1260, United States Innovation and Competition Act of 2021 and efforts to bolster US competitiveness against China in critical technology sectors; Monitor H.R.2731, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; CURES 2.0 Discussion Draft; Implementation of PL 117-2, American Rescue Plan Act of 2021; Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260); Ongoing monitoring of CDC surveillance funding; Monitor S. 1260, United States Innovation and Competition Act of 2021 and efforts to bolster US competitiveness against China in critical technology sectors; Monitor H.R. 2731, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors; H.R.791/S.236, Tracking COVID-19 Variants Act; H.R. 5376, Build Back Better Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Healthcare issues related to clinical laboratories; H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; S. 610, the Protecting Medicare and American Farmers from Sequester Cuts Act, provisions relating to delays in data collection and rate changes pertinent to the Medicare Clinical Laboratory Fee Schedule, mitigation of the Medicare sequester and rate changes pertinent to the Medicare Physician Fee Schedule, and suspension of certain statutory pay-as-you-go requirements; S. 701, the Allergy Testing Access Act, provisions relating to Medicare coverage of certain allergy tests; H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing; S. 1605, the National Defense Authorization Act for Fiscal Year 2022, provisions relating to TRICARE coverage of preconception and prenatal carrier screening; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; and Federal policy relating to use of pharmacogenetic information, including a discussion draft of the Right Drug Dose Now Act.

S.2022, Ending the Diagnostic Odyssey Act.

Client expense: Not reported · Firm income: $20,000

S.2022, Ending the Diagnostic Odyssey Act.

Client expense: Not reported · Firm income: $20,000

Issues related to genomics, sequencing, and surveillance; S. 2022, Ending the Diagnostic Odyssey Act; CURES 2.0 Discussion Draft

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; CURES 2.0 Discussion Draft; Implementation of PL 117-2, American Rescue Plan Act of 2021; Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260); Ongoing monitoring of CDC surveillance funding; Monitor S. 1260, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors; H.R.791/S.236, Tracking COVID-19 Variants Act; H.R. 5376, Build Back Better Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Policies impacting Medicare and Medicaid coverage and reimbursement for whole genome sequencing clinical laboratory services; S.2022, Ending the Diagnostic Odyssey Act of 2021.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2022, The "Diagnostic Odyssey Act" and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance.

Client expense: Not reported · Firm income: $50,000

S.2022, Ending the Diagnostic Odyssey Act.

Client expense: Not reported · Firm income: $20,000

Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; CURES 2.0 Discussion Draft; Implementation of PL 117-2, American Rescue Plan Act of 2021; Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260); Ongoing monitoring of CDC surveillance funding; Monitor S. 1260, Endless Frontier Act and efforts to bolster US competitiveness against China in critical technology sectors; H.R.791/S.236, Tracking COVID-19 Variants Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2022, The "Diagnostic Odyssey Act" and 21st Century Cures 2.0 legislation. 21st Century Cures Act. Issues related to genomics, sequencing, and surveillance.

Client expense: Not reported · Firm income: $20,000